��������

Ed Cannon is the current director at Akston Biosciences. Prior to this, they were the president and CEO of Elixir Pharmaceuticals from January 2001 to December 2004.

Elixir Pharmaceuticals was founded with the goal of creating a new category of pharmaceutical products - drugs that slow aging, forestall the disease and disability that accompany aging, and extend youthful health, vigor and productivity. This was made possible by recent insight that the pace of aging is controlled by specific genes (“longevity genes”), which can be altered to slow aging, extend life span, and confer resistance to the broad spectrum of diseases that accompany aging.

Cannon was instrumental in the success of Elixir Pharmaceuticals, helping to revolutionize aging research and provide genetically validated targets for drug discovery. Under their leadership, the company made significant progress in its goals, developing a strong portfolio of products and technologies.

Now at Akston Biosciences, Cannon is continuing their work in the field of longevity, working on new ways to extend the healthy human lifespan.